Close Menu

SAN FRANCISCO (GenomeWeb) – Natera said that while it is on track to launch a CLIA-validated version of its bespoke circulating tumor DNA assay, Signatera, in the second quarter of this year, it plans to continue to focus on forging deals with pharmaceutical companies, rather than on selling it for clinical testing, until it has secured coverage decisions from third-party payors.  

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.